TriangleNCT04628780 · OUTCOME
Progression-Free Survival (PFS) Based on Investigator Assessment in Participants
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Baseline through up to 2 years or until disease progression
What was measured
PFS is defined as time from start date of treatment to the date of first documentation of PD or death due to any cause, or censoring, whichever occurred first. Both new anti-cancer therapy given prior to PD or death and no PD by the end of follow-up are censoring events.
Analysis population: The full analysis set includes all enrolled participants.
Groups in this outcome
PF-07209960 1 mg SC
Participants with advanced or metastatic solid tumors were treated with PF-07209960 1 mg as a subcutaneous (SC) administration every 2 weeks (Q2W) for a maximum duration of 10.9 months.
PF-07209960 3 mg SC
Participants with advanced or metastatic solid tumors were treated with PF-07209960 3 mg as a SC administration Q2W for a maximum duration of 5.1 months.
PF-07209960 10 mg SC
Participants with advanced or metastatic solid tumors were treated with PF-07209960 10 mg as a SC administration Q2W for a maximum duration of 3.4 months.
PF-07209960 15 mg SC
Participants with advanced or metastatic solid tumors were treated with PF-07209960 15 mg as a SC administration Q2W for a maximum duration of 5.8 months.
PF-07209960 20 mg SC
Participants with advanced or metastatic solid tumors were treated with PF-07209960 20 mg as a SC administration Q2W for a maximum duration of 13.6 months.
PF-07209960 30 mg SC
Participants with advanced or metastatic solid tumors were treated with PF-07209960 30 mg as a SC administration Q2W for a maximum duration of 12.6 months.
| Group | Source count |
|---|---|
| PF-07209960 1 mg SC | 4 |
| PF-07209960 3 mg SC | 4 |
| PF-07209960 10 mg SC | 4 |
| PF-07209960 15 mg SC | 3 |
| PF-07209960 20 mg SC | 16 |
| PF-07209960 30 mg SC | 6 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| PF-07209960 1 mg SC | 2.8 | Not reported | 1.4 | NA | Upper limit of 95% CI was not reached due to fewer number of participants with event. |
| PF-07209960 3 mg SC | 2.8 | Not reported | 2.7 | NA | Upper limit of 95% CI was not reached due to fewer number of participants with event. |
| PF-07209960 10 mg SC | 3.8 | Not reported | 1.9 | NA | Upper limit of 95% CI was not reached due to fewer number of participants with event. |
| PF-07209960 15 mg SC | 1.6 | Not reported | 1.5 | NA | Upper limit of 95% CI was not reached due to fewer number of participants with event. |
| PF-07209960 20 mg SC | 1.8 | Not reported | 1.4 | 3.5 | Not reported |
| PF-07209960 30 mg SC | 2.0 | Not reported | 0.9 | NA | Upper limit of 95% CI was not reached due to fewer number of participants with event. |
Complete source fields
- classes
- categories
- measurements
- comment
- Upper limit of 95% CI was not reached due to fewer number of participants with event.
- group Id
- OG000
- lower Limit
- 1.4
- upper Limit
- NA
- value
- 2.8
- comment
- Upper limit of 95% CI was not reached due to fewer number of participants with event.
- group Id
- OG001
- lower Limit
- 2.7
- upper Limit
- NA
- value
- 2.8
- comment
- Upper limit of 95% CI was not reached due to fewer number of participants with event.
- group Id
- OG002
- lower Limit
- 1.9
- upper Limit
- NA
- value
- 3.8
- comment
- Upper limit of 95% CI was not reached due to fewer number of participants with event.
- group Id
- OG003
- lower Limit
- 1.5
- upper Limit
- NA
- value
- 1.6
- group Id
- OG004
- lower Limit
- 1.4
- upper Limit
- 3.5
- value
- 1.8
- comment
- Upper limit of 95% CI was not reached due to fewer number of participants with event.
- group Id
- OG005
- lower Limit
- 0.9
- upper Limit
- NA
- value
- 2.0
- denoms
- counts
- group Id
- OG000
- value
- 4
- group Id
- OG001
- value
- 4
- group Id
- OG002
- value
- 4
- group Id
- OG003
- value
- 3
- group Id
- OG004
- value
- 16
- group Id
- OG005
- value
- 6
- units
- Participants
- description
- PFS is defined as time from start date of treatment to the date of first documentation of PD or death due to any cause, or censoring, whichever occurred first. Both new anti-cancer therapy given prior to PD or death and no PD by the end of follow-up are censoring events.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Participants with advanced or metastatic solid tumors were treated with PF-07209960 1 mg as a subcutaneous (SC) administration every 2 weeks (Q2W) for a maximum duration of 10.9 months.
- id
- OG000
- title
- PF-07209960 1 mg SC
- description
- Participants with advanced or metastatic solid tumors were treated with PF-07209960 3 mg as a SC administration Q2W for a maximum duration of 5.1 months.
- id
- OG001
- title
- PF-07209960 3 mg SC
- description
- Participants with advanced or metastatic solid tumors were treated with PF-07209960 10 mg as a SC administration Q2W for a maximum duration of 3.4 months.
- id
- OG002
- title
- PF-07209960 10 mg SC
- description
- Participants with advanced or metastatic solid tumors were treated with PF-07209960 15 mg as a SC administration Q2W for a maximum duration of 5.8 months.
- id
- OG003
- title
- PF-07209960 15 mg SC
- description
- Participants with advanced or metastatic solid tumors were treated with PF-07209960 20 mg as a SC administration Q2W for a maximum duration of 13.6 months.
- id
- OG004
- title
- PF-07209960 20 mg SC
- description
- Participants with advanced or metastatic solid tumors were treated with PF-07209960 30 mg as a SC administration Q2W for a maximum duration of 12.6 months.
- id
- OG005
- title
- PF-07209960 30 mg SC
- param Type
- MEDIAN
- population Description
- The full analysis set includes all enrolled participants.
- reporting Status
- POSTED
- time Frame
- Baseline through up to 2 years or until disease progression
- title
- Progression-Free Survival (PFS) Based on Investigator Assessment in Participants
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice